Objectives To characterize the frequency of opioid prescribing for pediatric headache in both ambulatory and emergency department (ED) settings, including prescribing rates by provider type.
H
eadache is a common complaint among children that results in frequent visits to outpatient clinics and accounts for more than 500 000 emergency department (ED) visits annually. 1, 2 Although headaches encompass a large number of etiologies, 2 primary headache disorders-migraine and tension-type-are the most prevalent. 3, 4 Both disorders have a natural history of episodic exacerbation, and both can become chronic. 5, 6 A range of effective and specific abortive medications exist, including simple analgesics, anti-inflammatory agents, triptans, and dopamine antagonists. 7, 8 In contrast, opioid medications are explicitly discouraged for primary headache disorders because they may potentiate migraine pathophysiology at the molecular level by blunting the response to targeted abortive therapies and converting episodic to chronic headache. [9] [10] [11] As a result, the American Academy of Neurology recently published a statement recommending against the use of opioids for primary headache. 12 Despite this recommendation, however, several studies have suggested that opioids are frequently prescribed for pediatric headache, particularly in the ED setting. 1, 2, [13] [14] [15] [16] [17] [18] The medical treatment of pediatric primary headache disorders is particularly important in the context of the ongoing epidemic of opioid misuse and opioid-related deaths in North America. In response to this epidemic, researchers have begun to elucidate specific risk factors for opioid misuse, and a correlation between the receipt of medical opioid prescription and subsequent diversion to nonmedical use, abuse, or overdose has been reported. [19] [20] [21] [22] Moreover, studies of patient-level risk factors suggest that adolescents may be a high-risk population for opioid misuse. 23, 24 Less is known about medical provider or health care setting factors associated with opioid prescribing, particularly regarding children and adolescents. Therefore, we sought to describe the rates and variability of opioid prescribing to children and adolescents with primary headaches in both ambulatory and ED settings.
Methods
We performed a retrospective cohort study of children (age 7-12 years) and adolescents (age 13-17 years) enrolled in Washington State Medicaid between January 1, 2012, and September 30, 2015. Data from 2011 were also included to allow assessment of patient comorbidities at baseline. Washington provided Medicaid enrollment data and medical claims, as well as Prescription Drug Monitoring Program (PDMP) data linked at the beneficiary level. The PDMP is an electronic record
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Portions of this study were presented as a poster at the Pediatric Academic Societies annual meeting, May 6-9, 2017, San Francisco, California. We included all ED visits with a paid Medicaid claim for residents of Washington State. To exclude other causes of secondary headache and conditions that may require opioid pain management, we excluded any patients with a history of cancer, traumatic brain injury, or hydrocephalus. All ICD-9 codes excluded are listed in Table I (available at www.jpeds.com). We would expect the vast majority of patients with a headache secondary to a ventriculoperitoneal shunt or intracranial surgery to be excluded by those codes. We excluded beneficiaries who were enrolled for less than 3 months during the previous year, to ensure that sufficient data were available for assessing patient health at baseline. We excluded patients who were eligible for both Medicare and Medicaid, because linked Medicare data were unavailable. Finally, we excluded patients who received hospice or nursing home care at any time during the study period.
Outcomes
The primary outcome was any outpatient-dispensed opioid prescription prescribed within 1 day of the index visit. We matched prescribing date to within 1 day after the index visit to account for ED visits that spanned midnight. We included buprenorphine, codeine, fentanyl, hydrocodone, hydromorphone, levorphanol, meperidine, methadone, morphine, oxycodone, oxymorphone, tapentadol, and tramadol. We included tablets, syrups/suspensions, films, and transdermal patches, and we excluded other formulations (eg, powders, sprays). In addition, we recorded the total outpatient-dispensed morphine milligram equivalents (MME) prescribed within 1 day of the index visit. We used the following conversion factors to calculate MMEs: buprenorphine patch, 12.6; buprenorphine tablet, 30; codeine, 0.15; fentanyl patch, 7.2; hydrocodone, 1; hydromorphone,4; levorphanol, 11; meperidine, 0.1; methadone, 3; morphine, 1; oxycodone, 1.5; oxymorphone, 3; tapentadol, 0.4; and tramadol, 0.1.
28-30
Measures Visit characteristics included patient demographics (age, sex, race/ethnicity) and enrollment in Medicaid fee-for-service vs managed care programs. We also included an indicator for the care setting (ED vs ambulatory care) and an indicator for whether each visit involved a physician with a self-reported primary specialization of pediatrics, reported to the National Plan and Provider Enumeration System National Provider Identifier (NPI) Registry. Finally, we include an indicator for calendar quarter to adjust for seasonality, and an indicator for calendar year to adjust for annual differences.
Statistical Analyses
We described characteristics of headache visits that resulted in an opioid prescription, compared with those that did not, across different care settings. We used the t test, c 2 test, or Wilcoxon test as appropriate to identify unadjusted associations with opioid prescribing. We also described rates of opioid prescribing over time, as well as the types of opioids that were prescribed. We used a multivariable logistic regression model to assess the association of pediatric specialty with the outcome of any dispensed opioid. The unit of analysis was a headacherelated visit. Models included the measures described above, and standard errors were clustered at the patient level. Because opioid prescribing practices may vary by care setting, we included an interaction term between care setting and pediatric specialty. Estimated model results are presented as marginal effects. All data management and statistical analyses were performed in R version 3.4.1 (R Institute for Statistical Computing, Vienna, Austria) and Stata MP 14.0 (StataCorp, College Station, Texas).
Results
The study cohort included 8878 ED and 42 842 ambulatory care visits for headaches (Figure 1 , available at www.jpeds.com). Characteristics of the study sample are described in Table II . There were more adolescents (59.4%) compared with younger patients (40.6%), and there was a predominance of females (63.2%). A pediatric provider was identified in 30.5% of all visits. The mean (SD) number of visits per patient during the study period was 1.63 (1.47).
The overall unadjusted opioid prescribing rate was 1.5% (95% CI, 1.4%-1.6%). In the ED setting, 3.9% of visits resulted in an opioid prescription, compared with 1.0% in the ambulatory setting (P < .001). When prescribed, the mean dose was higher in the ambulatory setting than the ED (103.5 MME vs 72.9 MME; P = .002).
There was a temporal trend toward decreasing opioid prescribing during the study period regardless of setting (Figure 2) . ED prescribing showed a decrease from 5.1% in 2012 to 3.5% in 2015 (P = .006), and the rate in the ambulatory setting remained <2% at the start and end of the study period. The top 3 opioid medications prescribed were hydrocodone (54%), codeine (38%), and oxycodone (8%).
Provider training was associated with opioid prescribing in both the ambulatory and ED settings (Table III) . Compared with visits with an opioid, visits without an opioid were more likely to involve a pediatrician in both the ED (20.8% vs 9.7%; P < .001) and ambulatory care (32.7% vs 24.9%; P = .001) settings. In the ambulatory care setting, the probability that a visit with a pediatrician resulted in an opioid prescription was an absolute 0.31 percentage point lower than that for a visit without Volume 204 • January 2019 a pediatrician (P < .009). In the ED setting, the probability that a visit with a pediatric-trained provider resulted in an opioid prescription was an absolute 2.7 percentage points lower, or a relative risk reduction of 58.8%, than the probability for a visit without a pediatric-trained provider (P < .001). The effects of pediatric training varied significantly across settings (P value for interaction <.001).
In the full multivariable model (Table IV ; available at www.jpeds.com), the probability of receiving an opioid prescription for headache was slightly higher (0.87 percentage point) among adolescents age 13-17 years compared with children age 7-12 years. Compared with white patients, the probability of receiving an opioid was lower for some racial/ ethnic groups including Hawaiian/Pacific Islanders, Asians, and Hispanics (−1.41, −1.22, and −0.96 percentage points, respectively). There was no significant difference in the probability of receiving an opioid for female vs male patients.
Discussion
In this state-wide cohort of pediatric and adolescent patients, we found low overall rates of opioid prescribing for ambulatory and ED visits related to primary headache. Opioid prescribing rates were higher in the ED than in the ambulatory setting, but decreased over the 3-year study period. We observed a lower rate of opioid prescribing by pediatric-trained physicians in both settings, with a more pronounced effect in the ED setting. Our overall rate of opioid prescribing for children and adolescents with primary headache was lower than that reported previously. Early studies of pediatric opioid prescribing suggested that opioids were prescribed to 8%-46% of children and adolescents with headache. [16] [17] [18] Although these studies included data related to opioids and headache, most did not focus exclusively on headache and did not specify whether secondary headaches (including trauma) were excluded. Our significantly lower rates of opioid prescribing may be related to our broader exclusion of ICD-9 codes indicating secondary causes of headache than was done in previous studies. The highest rates of opioid prescribing for pediatric headache were reported by Devries et al, who identified opioid prescriptions among 46% of adolescent headache excluding trauma, including 28% with a diagnosis of migraine. 1 However, the Devries study used medical and pharmacy claims data over a 1-year period to identify adolescents with an index claim diagnosis of headache who had received an opioid prescription over the same period, and it is possible that opioids were prescribed for another reason and misattributed to treatment of headache.
Among previous studies limited to pediatric headache in the ED setting, reported rates of opioid use range from 5.4% to 16.8% of headaches overall, and 5.6% to 20.9% of migraines specifically. 2, 13, 15 Although the lower rate in our study could reflect geographical differences between our statewide cohort and national datasets, this is unlikely, because previous analyses using national data have consistently shown lower rates of opioid prescribing in the Northeast and higher rates in the South and West 17, 18 ; more likely, our results suggest a true decrease in prescribing more recently, perhaps as a result of growing awareness of the potential harm of opioids in chronic conditions. This is supported by our observation of decreasing rates of opioid prescribing across our study period, which is a reversal of the pattern observed in several earlier studies through 2010. [16] [17] [18] 31 Finally, earlier ED studies 7 used survey data that captured medications given during the ED encounter, including oral and parenteral opioids, and our study examined only written prescriptions that would be filled by patients after an encounter, which may also account for differences between our findings and previous reports.
The most commonly prescribed opioids in our cohort were hydrocodone (54%) and codeine (38%). This is consistent with previous descriptions of general opioid prescribing in the pediatric population, 16, 18, 31 and codeine or codeine-containing agents were the most commonly used opioid in the Canadian Pediatric ED study by Richer et al. 14 We were particularly concerned by the high proportion of codeine prescribed in our series, given warnings from the American Academy of Pediatrics and the Food and Drug Administration regarding the potential danger of codeine in the pediatric population related to genetic variability in metabolism. 32 One of the novel findings of our study is the significantly lower prescribing rate of opioids by pediatricians compared with nonpediatricians. This was true for both the ambulatory and ED settings, but more pronounced in the ED. When pediatricians were not involved in a visit for headache, opioids were almost 2.5-fold more likely to be prescribed. This is consistent with the higher reported use of opioids to treat adult headache 33 and may reflect differing patient expectations, different conditions most commonly treated by nonpediatricians, or differing attitudes toward opioid use by provider type. In any case, our findings suggest that further education regarding the role of opioids in pediatric primary headache might be most effectively targeted toward nonpediatricians caring for children, particularly in the ED setting.
Our study has some limitations. First, although we used the primary diagnosis to classify headache patients, it is possible that some patients may have received an opioid for an unrelated complaint, such as a traumatic injury. Although a definitive list of all traumatic injury codes could not be compiled and excluded, we included cases for which headache was the primary diagnosis and felt that this would likely exclude other major traumatic injuries, which if coexisting for a given visit likely would be coded as the primary diagnosis. Second, even though we used a broad range of ICD-9 codes related to common secondary causes of headache to define a cohort of children and adolescents treated for primary headache disorders, it is possible that we did not exclude all secondary headaches, resulting in misclassification. Similarly, provider specialty was self-reported to the NPI registry, and there is potential for misclassification of provider type. Finally, our findings are limited to Medicaid beneficiaries and should be verified in other payer populations.
In contrast to previous reports, we found an overall low rate of opioid prescribing for children and adolescents with headaches, with a decreasing temporal trend. ED opioid prescribing rates were nearly 4-fold higher than rates in ambulatory care settings, and pediatricians prescribe opioids less frequently than other specialties, particularly in the ED setting. Because the majority of children and adolescents requiring emergency care are treated outside of pediatric centers, further education related to appropriate opioid prescribing for the pediatric population might focus on these settings. ■ 
